x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

OncoPharm

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

science

All Episodes

00:19:36

Updates from December 2020

OncoPharm ·

2021/01/07

The 1st episode of 2021 covers 5 FDA updates from December 2020 -Pralsetinib for RET-mutated medullary thyroid cancer -The new HER2-targeting margetuximab -Selinexor and the Boston study -Relugolix, an oral GnRH antagonist -Adjuvant osimertinib approved (ADAURA)

en

00:15:25

Trastuzumab

OncoPharm ·

2020/12/31

Our Foundations of Oncopharm series returns to discuss the history and use of trastuzumab.

en

00:11:53

Best Of 2020

OncoPharm ·

2020/12/23

Highlighting some of the bright spots, oncopharm & otherwise, for our Holiday episode. Best new drug? Best study? Best movie to take my mind off of a pandemic? Enjoy this episode with a glass of Holiday Cheer.

en

00:16:50

COVID Vaccines In Cancer Patients - What We Don't Know

OncoPharm ·

2020/12/17

COVID-19 Vaccines are here!!! Will they work in patients on chemo? What about immunotherapy? Without firm answers to such questions we might as well talk about mRNA vaccines, the breakout star of 2020.

en

00:14:42

Breast Cancer Updates Dec. 2020

OncoPharm ·

2020/12/11

First up we discuss RxPonder and what it adds to adjuvant treatment of breast cancer in the context of TailoRx. Then we discuss a recent study (https://jamanetwork.com/journals/jama/fullarticle/2774295)of additional capecitabine following adjuvant chemo in TNBC and what it adds in the context of CREATE-X.

en

00:18:33

Colon Cancer Updates (IDEA & Keynote - 177)

OncoPharm ·

2020/12/03

Final OS results are now available for IDEA - 3 vs. 6 months of adjuvant chemotherapy for colon cancer: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30527-1/fulltext Keynote-177 (pembrolizumab for MSI-H/dMMR metastatic colorectal cancer) was presented at ASCO, but interim results are now published as well: https://www.nejm.org/doi/full/10.1056/NEJMoa2017699

en

00:15:42

CLOT

OncoPharm ·

2020/11/24

The Landmarks in OncoPharm series returns to discuss the practice-changing CLOT trial of a LMWH vs. a vitamin K antatogist for treating cancer-associated VTE. CLOT: https://www.nejm.org/doi/full/10.1056/nejmoa025313

en

00:12:46

Pembrolizumab for TNBC & CML Updates

OncoPharm ·

2020/11/19

Pembro gets an approval for triple negative breast cancer with quite high PD-L1 expression based on Keynote-355 (https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1000). Some reassuring information on TKI discontinuation in CML from the LAST study (doi:10.1001/jamaoncol.2020.5774) and an interesting method of identifying predictors of TKI adherence in CML (https://journals.sagepub.com/doi/pdf/10.1177/1078155220970616).

en

00:14:09

Ifosfamide

OncoPharm ·

2020/11/12

Our Landmarks of OncoPharm series returns with Ifosfamide

en

00:14:37

BELLINI

OncoPharm ·

2020/11/05

The BELLINI trial of venetoxlax in multiple myeloma was put on hold last year due to increased mortality. It's now published (https://doi.org/10.1016/S1470-2045(20)30525-8), so we take a look at the data and the myriad of supportive care concerns.

en

00:17:26

Updates On Keynote-426, Ph+ ALL, & Post - AlloHSCT...

OncoPharm ·

2020/10/29

Discussing three recent publications: 1. Updated results of Keynote-426 (https://doi.org/10.1016/S1470-2045(20)30436-8) 2. Ph+ ALL tx with dasatinib/prednisone --> blinatumomab (https://www.nejm.org/doi/full/10.1056/NEJMoa2016272) 3. Decitabine + G-CSF to prevent AML relapse following alloHSCT (https://ascopubs.org/doi/pdf/10.1200/JCO.19.03277)

en

00:14:57

Monthly Immunotherapy Expanded Approvals Update

OncoPharm ·

2020/10/21

Another month, another 2 expanded FDA-approvals: nivolumab/ipilimumab for malignant pleural mesothelioma and pembrolizumab for relapsed/refractory classical Hodgkin's lymphoma.

en

00:13:33

Fulvestrant's Fumbled Dosing

OncoPharm ·

2020/10/15

Fulvestrant's standard dosing is now 500 mg IM on Days 1, 14, 29 & then monthly thereafter. Its initial FDA-approved doing was half that with no loading dose, 250 mg IM monthly. So, how did we come to underdose an antineoplastic for almost a decade?

en

00:19:09

Dexamethasone

OncoPharm ·

2020/10/08

Foundations in #OncoPharm returns to discuss everyone's favorite antineoplastic, dexamethasone, which is also an anti-emetic, and an oncology pre-med among other things.

en

00:15:45

IMpower 110 & Checkmate 153

OncoPharm ·

2020/10/01

Another week, another 2 studies of checkpoint inhibitors in NSCLC to talk about. IMpower 110: https://www.nejm.org/doi/full/10.1056/NEJMoa1917346 Checkmate-153: https://ascopubs.org/doi/full/10.1200/JCO.20.00131

en

00:24:20

ESMO 2020 & Beyond

OncoPharm ·

2020/09/24

Updates from ESMO 2020 & more on: Bladder Cancer (JAVELIN Bladder 100 & DANUBE) Lung Cancer (ADAURA & CROWN) Breast Cancer (ASCENT, IMPASSION 130/131, monarchE) And the first major publication of drugging the "undrugable" KRAS

en

00:14:19

TAX 327

OncoPharm ·

2020/09/17

The Landmarks in OncoPharm series returns to discuss a major breakthrough in treating advanced prostate cancer, TAX-327, which at the time established docetaxel as a new standard of care for metastatic prostate cancer that was (at that time) considered hormone-refractory. TAX 327: https://www.nejm.org/doi/full/10.1056/NEJMoa040720

en

00:11:47

Pralsetinib

OncoPharm ·

2020/09/11

We have a new drug, pralsetinib, to discuss. It's the 2nd RET inhibitor approved for RET-fusion (+) metastatic NSCLC.

en

00:16:55

BROCADE3

OncoPharm ·

2020/09/03

After brief diatribes on PO azacitidine and COMBI-AD's 5-year non-OS analysis, we focus on BROCADE3 and the background on BRCA-mutated metastatic breast cancer treatment. BROCADE3: https://doi.org/10.1016/S1470-2045(20)30447-2

en

00:19:15

Alopecia

OncoPharm ·

2020/08/27

Chemotherapy-induced alopecia is the next in our series on Foundational #OncoPharm topics.

en

423 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter